A biotechnology company in Haifa, Israel, that grows human, animal, and plant cells at industrial scale using a three-dimensional cell-expansion platform. Its placenta-derived PLX cell therapies target inflammatory and muscle conditions, while the same technology also feeds cultivated-meat and agricultural projects. Founded from stem-cell patents developed during founder Shai Meretzki's PhD at the Technion, it was long known as Pluristem Therapeutics before shortening its name to Pluri in 2022 — a nod to "pluripotent" cells.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +1.43M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.